NewLimit
Backed by
Raised $130M Series B on May 6, 2025
NewLimit is a biotechnology company working to radically extend human healthspan. They are developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells.
Scientist/Senior Scientist, Metabolism
South San Francisco · Posted on Jul 21, 2025
Facilities Manager (Part Time)
South San Francisco CA · Posted on Jul 16, 2025
Scientific Talent Partner (Part Time)
South San Francisco · Posted on Jul 16, 2025
Senior/Research Associate, Functional Genomics
South San Francisco, CA · Posted on Jun 23, 2025
Senior/Research Associate, Metabolism
South San Francisco · Posted on Jun 20, 2025
Group Leader, Immunology
South San Francisco, CA · Posted on Apr 21, 2025
Scientist/Senior Scientist, Functional Genomics
South San Francisco, CA · Posted on Apr 21, 2025
Explore similar companies to NewLimit
Manifold Bio
Tissue-targeted medicines, designed in vivo.
Colossal
The de-extinction company.
Loyal
Extending the lifespan of dogs.
Nudge
Whole-brain interfaces for everyday life.
Latent Labs
Making biology programmable.
Science
A brighter tomorrow enabled by neural engineering.
Cradle
Design better proteins.
Cortical Labs
Lab-grown neurons with silicon chips.
Candid Health
Easy, automated medical billing.